AUTL (Autolus Pharma) שולי הרווח הגולמי

Changes in gross margin reflect operating profit dynamics, with 35.80 serving as the current value of the indicator. Autolus Therapeutics (AUTL) has established ultra-fast transportation of biomaterials between centers and laboratories. The development of CAR-T therapy using its own platform to combat lymphomas reduces regulatory risks. Business growth is driven by the launch of in-house production, the expected approval of Obe-cel, and strategic alliances with pharma behemoths.
פילוחי מדדים מקיפים ואנליטיקה עבור Autolus Pharma (AUTL)

Scaling the IT complexes for the production of Autolus Therapeutics (AUTL) obe-cel CAR-T therapy requires strict cost control for the manufacture of each dose. Monthly gross margin reflects the portion of revenue minus the cost of goods sold, measuring capital efficiency and operational density, which allows investors to promptly identify the risk of margin degradation and asset overpayment.